RAPT Therapeutics Inc. Common Stock
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
RAPT Overview
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$22.6000 |
Previous Close Volume |
324250 |
Latest News
-
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
12 Nov 2024 10:03:07
https://rapt.com/news/rapt-therapeutics-reports-third-quarter-2024-financial-results/
- Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury 11 Nov 2024 09:33:06
-
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
08 Aug 2024 10:34:24
https://rapt.com/news/rapt-therapeutics-reports-second-quarter-2024-financial-results/
-
RAPT Therapeutics Reports First Quarter 2024 Financial Results
09 May 2024 09:50:13
https://rapt.com/news/rapt-therapeutics-reports-first-quarter-2024-financial-results/
- RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients 09 Apr 2024 13:50:08
-
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
07 Mar 2024 10:20:21
https://rapt.com/news/rapt-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results/
- RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting 05 Mar 2024 17:50:16
-
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
20 Feb 2024 09:05:30
https://rapt.com/news/rapt-therapeutics-announces-clinical-hold-on-studies-evaluating-zelnecirnon/
- RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations 13 Feb 2024 10:05:05
- RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference 31 Jan 2024 09:20:40
- RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy 27 Nov 2023 11:30:08
-
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
13 Nov 2023 10:39:14
https://rapt.com/news/rapt-therapeutics-reports-third-quarter-2023-financial-results/
- RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC 03 Nov 2023 13:45:22
- RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November 01 Nov 2023 16:45:17